Oxn 5/2.5 mg pr    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
226間質性膀胱炎(ハンナ型)3

226. 間質性膀胱炎(ハンナ型) [臨床試験数:133,薬物数:151(DrugBank:46),標的遺伝子数:48,標的パスウェイ数:137
Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 133 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-018118-21-CZ
(EUCTR)
09/08/201010/06/2010not applicableAn exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome)
MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg
Product Code: OXN 5/2.5 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg
Product Code: OXN 10/5 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 20mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg
Product Code: OXN 20/10 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release t
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: no
70Hungary;Czech Republic;Germany;United Kingdom
2EUCTR2009-018118-21-HU
(EUCTR)
04/08/201021/05/2010not applicableAn exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome)
MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg
Product Code: OXN 5/2.5 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg
Product Code: OXN 10/5 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 20mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg
Product Code: OXN 20/10 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release t
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: no
70Czech Republic;Hungary;Germany;United Kingdom
3EUCTR2009-018118-21-DE
(EUCTR)
10/05/2010not applicableAn exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome)
MedDRA version: 14.1;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg
Product Code: OXN 5/2.5 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg
Product Code: OXN 10/5 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 20mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg
Product Code: OXN 20/10 mg PR
Other descriptive name: OXYCODONE HYDROCHLORIDE
Other descriptive name: NALOXONE HYDROCHLORIDE
Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release t
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: no
70Czech Republic;Hungary;Germany;United Kingdom